Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Sean F. Scanlan, the Chief Innovation Officer at Treace Medical (TASE:BLWV) Concepts, Inc. (NASDAQ:TMCI), reported selling 50,000 shares of the company’s common stock on March 17, 2025. The shares were sold at a weighted average price of $7.9692, resulting in a total transaction value of approximately $398,460.
The sale was part of a series of transactions that also included the exercise of stock options, where Scanlan acquired 50,000 shares at a price of $1.05 per share. Following these transactions, Scanlan holds 364,081 shares directly, including 325,098 restricted stock units. According to InvestingPro analysis, TMCI appears slightly undervalued at current levels, with additional insights available in the comprehensive Pro Research Report covering this healthcare innovator.
These transactions were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks, helping to avoid potential insider trading accusations.
In other recent news, Treace Medical Concepts Inc. reported its fourth-quarter 2024 earnings, exceeding expectations with a loss of $0.01 per share compared to the anticipated loss of $0.04. The company also surpassed revenue forecasts, achieving $68.7 million against the expected $67.02 million, marking a 10.4% year-over-year growth. Despite these positive financial results, Stifel analysts maintained a Hold rating on Treace Medical with a price target of $9.00, following a detailed discussion with the company’s executives about future strategies.
During this discussion, Treace Medical’s management shared their conservative assumptions for 2025, indicating potential upside surprises if market conditions remain favorable. The company plans to introduce several new products in 2025, including Nanoplasty/Percuplasty and SpeedMTP/SpeedAkin, which are expected to drive growth. For 2025, Treace Medical projects revenue growth between 7% and 10%, with a target of achieving breakeven adjusted EBITDA. The company also aims to reduce its cash burn by 50% compared to 2024.
Analysts from Stifel expressed cautious optimism, suggesting that 2025 could be a stronger year for Treace Medical, contingent upon successful product launches and market conditions. The company continues to focus on expanding its market share in the foot-and-ankle sector, which remains a significant area of interest for Treace Medical. Overall, these recent developments highlight the company’s strategic direction and financial outlook for the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.